These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 21525172)

  • 1. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
    Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
    Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
    Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
    J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
    Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
    Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.
    Dabora SL; Franz DN; Ashwal S; Sagalowsky A; DiMario FJ; Miles D; Cutler D; Krueger D; Uppot RN; Rabenou R; Camposano S; Paolini J; Fennessy F; Lee N; Woodrum C; Manola J; Garber J; Thiele EA
    PLoS One; 2011; 6(9):e23379. PubMed ID: 21915260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
    Davies DM; Johnson SR; Tattersfield AE; Kingswood JC; Cox JA; McCartney DL; Doyle T; Elmslie F; Saggar A; de Vries PJ; Sampson JR
    N Engl J Med; 2008 Jan; 358(2):200-3. PubMed ID: 18184971
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting lymphangioleiomyomatosis and bilateral angiomyolipomas in a patient with tuberous sclerosis.
    Uzzo RG; Libby DM; Vaughan ED; Levey SH
    J Urol; 1994 Jun; 151(6):1612-5. PubMed ID: 8189576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangioleiomyomatosis.
    Johnson SR; Taveira-DaSilva AM; Moss J
    Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy.
    Cleary-Goldman J; Sanghvi AV; Nakhuda GS; Robinson JN
    J Matern Fetal Neonatal Med; 2004 Feb; 15(2):132-4. PubMed ID: 15209123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
    PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
    Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
    PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.
    Bujalance-Cabrera C; Vaquero-Barrios JM; Redel-Montero J; Caballero-Ballesteros L; Requejo-Jiménez A; Santos-Luna F
    Arch Bronconeumol; 2012 Dec; 48(12):479-81. PubMed ID: 22444789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral renal angiomyolipoma coexistent with pulmonary lymphangioleiomyomatosis and tuberous sclerosis.
    Yoshida S; Hayashi T; Ishii N; Yoshinaga A; Ohno R; Terao T; Watanabe T; Yamada T; Osada H
    Int Urol Nephrol; 2006; 38(3-4):413-5. PubMed ID: 17111084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.